Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

3 treatments under study, led by Tofacitinib

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed with results

Key Signals

2 with results50% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (2)

Trial Status

Completed1
Terminated1
Unknown1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06202560Not ApplicableCompleted

Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study

NCT06357169Not ApplicableTerminatedPrimary

Mechanical Intervention on the Scalp Microbiome: Setting the Stage for the Future Management of Cicatricial Alopecias

NCT03082560UnknownPrimary

Design and Validation of a New Assessment Tool for Lichen Planopilaris

Showing all 3 trials

Research Network

Common Treatments

  • Tofacitinib1
  • Boston Grade Of Activity In Lichen Planopilaris1
  • Venus Glow1

Active Sponsors

  • Massachusetts General Hospital1
  • University of Minnesota1
  • Institute of Dermatology, Thailand1

Top Investigators

Related Conditions

  • Frontal Fibrosing Alopecia2
  • Alopecia Areata1
  • Lichen Planopilaris1

Activity Timeline